The value of immunotherapy in head and neck cancer

References

• Economopoulou P, Perisanidis C, Giotakis EI. The emerging role of immunotherapy in head and neck squamous cell carcinoma (HNSCC): anti-tumor immunity and clinical applications. Ann Transl Med. 2016 May;4(9):173.
   PubMed Web of Science ®Google Scholar
• J F, I S, M E, et al. GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide: IARC cancer base no. 11 available at international agency for research on cancer; 2013 cited 2017 Dec 21. Available from: http://globocan.iarc.fr
   Google Scholar
• Schmitz S, Machiels JP. Targeting the tumor environment in squamous cell carcinoma of the head and neck. Curr Treat Options Oncol. 2016;17:37.
   PubMed Web of Science ®Google Scholar
• Sacco AG, Cohen EE. Current treatment options for recurrent or metastatic head and neck squamous cell carcinoma. J Clin Oncol. 2015;33:3305–3313.
   PubMed Web of Science ®Google Scholar
• Marur S, Forastiere AA. Head and neck cancer: changing epidemiology, diagnosis, and treatment. Mayo Clin Proc. 2008;83:489–501.
   PubMed Web of Science ®Google Scholar
• Seiwert TY, Cohen EE. State-of-the-art management of locally advanced head and neck cancer. Br J Cancer. 2005;92:1341–1348.
   PubMed Web of Science ®Google Scholar
• Wiegand S, Zimmermann A, Wilhelm T, et al. Survival after distant metastasis in head and neck cancer. Anticancer Res. 2015;35:5499–5502.
   PubMed Web of Science ®Google Scholar
• Jacobs C, Lyman G, Velez-Garcia E, et al. A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol. 1992;10:257–263.
   PubMed Web of Science ®Google Scholar
• Forastiere AA, Metch B, Schuller DE, et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. J Clin Oncol. 1992;10:1245–1251.
   PubMed Web of Science ®Google Scholar
• Gibson MK, Li Y, Murphy B, et al. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2005;23:3562–3567.
   PubMed Web of Science ®Google Scholar
• Rubin Grandis J, Melhem MF, Barnes EL, et al. Quantitative immunohistochemical analysis of transforming growth factor-alpha and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck. Cancer. 1996;78:1284–1292.
   PubMed Web of Science ®Google Scholar
• Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354:567–578.
   PubMed Web of Science ®Google Scholar
• Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008;359:1116–1127.
   PubMed Web of Science ®Google Scholar
• Vermorken JB, Trigo J, Hitt R, et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol. 2007;25:2171–2177.
   PubMed Web of Science ®Google Scholar
• Machiels JP, Haddad RI, Fayette J, et al. Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial. Lancet Oncol. 2015;16:583–594.
   PubMed Web of Science ®Google Scholar
• Burtness B, Haddad RI, Dinis J, et al. LUX-head and neck 2: randomized, double-blind, placebo-controlled, phase III trial of afatinib as adjuvant therapy after chemoradiation (CRT) in primary unresected, high/intermediate-risk, squamous cell cancer of the head and neck (HNSCC) patients (pts). J clin oncol. 2017;35:6001.
   Google Scholar
• Frisch M, Biggar RJ, Engels EA, et al. Association of cancer with AIDS-related immunosuppression in adults. Jama. 2001;285:1736–1745.
   PubMed Web of Science ®Google Scholar
• Grulich AE, van Leeuwen MT, Falster MO, et al. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet. 2007;370:59–67.
   PubMed Web of Science ®Google Scholar
• Birkeland SA, Storm HH, Lamm LU, et al. Cancer risk after renal transplantation in the Nordic countries, 1964-1986. Int J Cancer. 1995;60:183–189.
   PubMed Web of Science ®Google Scholar
• Dasgupta S, Bhattacharya-Chatterjee M, O’Malley BW Jr., et al. Inhibition of NK cell activity through TGF-beta 1 by down-regulation of NKG2D in a murine model of head and neck cancer. J Immunol. 2005;175:5541–5550.
   PubMed Web of Science ®Google Scholar
• Kuss I, Hathaway B, Ferris RL, et al. Decreased absolute counts of T lymphocyte subsets and their relation to disease in squamous cell carcinoma of the head and neck. Clin Cancer Res off J Am Assoc Cancer Res. 2004;10:3755–3762.
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Network. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature. 2015;517:576–582
   PubMed Web of Science ®Google Scholar
• Lopez-Albaitero A, Nayak JV, Ogino T, et al. Role of antigen-processing machinery in the in vitro resistance of squamous cell carcinoma of the head and neck cells to recognition by CTL. J Immunol. 2006;176:3402–3409.
   PubMed Web of Science ®Google Scholar
• Lalami Y, Awada A. Innovative perspectives of immunotherapy in head and neck cancer. From relevant scientific rationale to effective clinical practice. Cancer Treat Rev. 2016;43:113–123.
   PubMed Web of Science ®Google Scholar
• Ferris RL. Immunology and immunotherapy of head and neck cancer. J Clin Oncol. 2015;33:3293–3304.
   PubMed Web of Science ®Google Scholar
• Duffy SA, Taylor JM, Terrell JE, et al. Interleukin-6 predicts recurrence and survival among head and neck cancer patients. Cancer. 2008;113:750–757.
   PubMed Web of Science ®Google Scholar
• Zhang C, Zhang X, Chen XH. Inhibition of the interleukin-6 signaling pathway: a strategy to induce immune tolerance. Clin Rev Allergy Immunol. 2014;47:163–173.
   PubMed Web of Science ®Google Scholar
• Cheng F, Wang HW, Cuenca A, et al. A critical role for Stat3 signaling in immune tolerance. Immunity. 2003;19:425–436.
   PubMed Web of Science ®Google Scholar
• Jie H-B, Schuler PJ, Lee SC, et al. CTLA-4+ regulatory T cells increased in cetuximab-treated head and neck cancer patients suppress NK cell cytotoxicity and correlate with poor prognosis. Cancer Res. 2015;75:2200–2210.
   PubMed Web of Science ®Google Scholar
• Srivastava RM, Trivedi S, Concha-Benavente F, et al. CD137 stimulation enhances cetuximab-induced natural killer: dendritic cell priming of antitumor T-cell immunity in patients with head and neck cancer. Clin Cancer Res. 2017;23:707–716.
   PubMed Web of Science ®Google Scholar
• Yu GT, Bu LL, Huang CF, et al. PD-1 blockade attenuates immunosuppressive myeloid cells due to inhibition of CD47/SIRPalpha axis in HPV negative head and neck squamous cell carcinoma. Oncotarget. 2015;6:42067–42080.
   PubMedGoogle Scholar
• Davis RJ, Van Waes C, Allen CT. Overcoming barriers to effective immunotherapy: mDSCs, TAMs, and Tregs as mediators of the immunosuppressive microenvironment in head and neck cancer. Oral Oncol. 2016;58:59–70.
   PubMed Web of Science ®Google Scholar
• Chaturvedi AK, Engels EA, Pfeiffer RM, et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol. 2011;29:4294–4301.
   PubMed Web of Science ®Google Scholar
• Marur S, D’Souza G, Westra WH, et al. HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol. 2010;11:781–789.
   PubMed Web of Science ®Google Scholar
• Chaturvedi AK, Anderson WF, Lortet-Tieulent J, et al. Worldwide trends in incidence rates for oral cavity and oropharyngeal cancers. J Clin Oncol. 2013;31:4550–4559.
   PubMed Web of Science ®Google Scholar
• Kim HS, Lee JY, Lim SH, et al. Association between PD-L1 and HPV status and the prognostic value of PD-L1 in oropharyngeal squamous cell carcinoma. Cancer Res Treat. 2016;48:527–536.
   PubMed Web of Science ®Google Scholar
• Badoual C, Hans S, Merillon N, et al. PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer. Cancer Res. 2013;73:128–138.
   PubMed Web of Science ®Google Scholar
• Cabel L, Bidard FC, Servois V, et al. HPV circulating tumor DNA to monitor the efficacy of anti-PD-1 therapy in metastatic squamous cell carcinoma of the anal canal: A case report. Int J Cancer. 2017;141:1667–1670.
   PubMed Web of Science ®Google Scholar
• Hashibe M, Brennan P, Chuang SC, et al. Interaction between tobacco and alcohol use and the risk of head and neck cancer: pooled analysis in the international head and neck cancer epidemiology consortium. Cancer Epidemiol Biomarkers Prev. 2009;18:541–550.
   PubMed Web of Science ®Google Scholar
• Alexandrov LB, Ju YS, Haase K, et al. Mutational signatures associated with tobacco smoking in human cancer. Science (New York, NY). 2016;354:618–622.
   Google Scholar
• Chabanon RM, Pedrero M, Lefebvre C, et al. Mutational landscape and sensitivity to immune checkpoint blockers. Clin Cancer Res off J Am Assoc Cancer Res. 2016;22:4309–4321.
   PubMed Web of Science ®Google Scholar
• Haddad RI, Seiwert TY, Chow LQM, et al. Genomic determinants of response to pembrolizumab in head and neck squamous cell carcinoma (HNSCC). J clin oncol. 2017;35:6009.
   Web of Science ®Google Scholar
• Foy JP, Bertolus C, Michallet MC, et al. The immune microenvironment of HPV-negative oral squamous cell carcinoma from never-smokers and never-drinkers patients suggests higher clinical benefit of IDO1 and PD1/PD-L1 blockade. Ann Oncol. 2017;28:1934–1941.
   PubMed Web of Science ®Google Scholar
• Dionne LK, Driver ER, Wang XJ. Head and neck cancer stem cells: from identification to tumor immune network. J Dent Res. 2015;94:1524–1531.
   PubMed Web of Science ®Google Scholar
• Seiwert TY, Burtness B, Mehra R, et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol. 2016;17:956–965.
   PubMed Web of Science ®Google Scholar
• Bauml J, Seiwert TY, Pfister DG, et al. Pembrolizumab for platinum- and cetuximab-refractory head and neck cancer: results from a single-arm, phase II study. J Clin Oncol. 2017;35:1542–1549.
   PubMed Web of Science ®Google Scholar
• FDA approves pembrolizumab for head and neck cancer. cited 2018 Jan 17. Available from https://www.cancer.gov/news-events/cancer-currents-blog/2016/fda-pembrolizumab-hnscc
   Google Scholar
• Cohen EE, Harrington KJ, Tourneau CL, et al. Pembrolizumab vs methrotrexate or docetaxel or cetuximab for metastatic head and neck squamous cell carcinoma (Keynote 040). Ann Oncol 2017;28(suppl_5):v605–v649.
   Google Scholar
• FDA grants accelerated approval to pembrolizumab for first tissue/site agnostic indication. cited 2018 Jan 17. Available from: https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm560040.htm
   Google Scholar
• Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372:2509–2520.
   PubMed Web of Science ®Google Scholar
• De Schutter H, Spaepen M, Van Opstal S, et al. The prevalence of microsatellite instability in head and neck squamous cell carcinoma. J Cancer Res Clin Oncol. 2009;135:485–490.
   PubMed Web of Science ®Google Scholar
• Koy S, Plaschke J, Luksch H, et al. Microsatellite instability and loss of heterozygosity in squamous cell carcinoma of the head and neck. Head Neck. 2008;30:1105–1113.
   PubMed Web of Science ®Google Scholar
• Wang Y, Irish J, MacMillan C, et al. High frequency of microsatellite instability in young patients with head-and-neck squamous-cell carcinoma: lack of involvement of the mismatch repair genes hMLH1 AND hMSH2. Int J Cancer. 2001;93:353–360.
   PubMed Web of Science ®Google Scholar
• Blons H, Cabelguenne A, Carnot F, et al. Microsatellite analysis and response to chemotherapy in head-and-neck squamous-cell carcinoma. Int J Cancer. 1999;84:410–415.
   PubMed Web of Science ®Google Scholar
• NCT02358031. A study of pembrolizumab (MK-3475) for first line treatment of recurrent or metastatic squamous cell cancer of the head and neck (MK-3475-048/KEYNOTE-048). [cited 2018 Dec 17]. Available from: https://clinicaltrials.gov/ct2/show/NCT02358031.
   Google Scholar
• Uppaluri R, Zolkind P, Lin T, et al. Immunotherapy with pembrolizumab in surgically resectable head and neck squamous cell carcinoma. J clin oncol. 2016;34:TPS6110–TPS6110.
   Web of Science ®Google Scholar
• Uppaluri R, Zolkind P, Lin T, et al. Neoadjuvant pembrolizumab in surgically resectable, locally advanced HPV negative head and neck squamous cell carcinoma (HNSCC). J clin oncol. 2017;35:6012.
   Web of Science ®Google Scholar
• Ferris RL, Blumenschein G Jr., Fayette J, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016;375:1856–1867.
   PubMed Web of Science ®Google Scholar
• Harrington KJ, Ferris RL, Blumenschein G Jr., et al. Nivolumab versus standard, single-agent therapy of investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial. Lancet Oncol. 2017;18:1104–1115.
   PubMed Web of Science ®Google Scholar
• NCT03247712 neoadjuvant immunoradiotherapy in head & neck cancer. [cited 2018 Dec 17]. Available from: https://clinicaltrials.gov/ct2/show/NCT03247712
   Google Scholar
• NCT03003637 immunomodulation by the combination of ipilimumab and nivolumab neoadjuvant to surgery in advanced or recurrent head and neck carcinoma (IMCISION). [cited 2018 Jan 17]. Available from: https://clinicaltrials.gov/ct2/show/NCT03003637
   Google Scholar
• NCT03355560 adjuvant nivolumab after salvage resection in head and neck cancer patients previously treated with definitive therapy. [cited 2018 Jan 17]. Available from: https://clinicaltrials.gov/ct2/show/NCT03355560
   Google Scholar
• NCT02684253 screening trial of nivolumab with image guided, stereotactic body radiotherapy (SBRT) versus nivolumab alone in patients with metastatic head and neck squamous cell carcinoma (HNSCC). Available from: https://clinicaltrials.gov/ct2/show/NCT02684253
   Google Scholar
• Ferris RL, Gonçalves A, Baxi SS, et al. LBA46An open-label, multicohort, phase 1/2 study in patients with virus-associated cancers (CheckMate 358): safety and efficacy of neoadjuvant nivolumab in squamous cell carcinoma of the head and neck (SCCHN). Ann Oncol. 2017;28:mdx440.041-mdx440.041.
   Web of Science ®Google Scholar
• Economopoulou P, Kotsantis I, Psyrri A. Checkpoint inhibitors in head and neck cancer: rationale, clinical activity, and potential biomarkers. Curr Treat Options Oncol. 2016;17:40.
   PubMed Web of Science ®Google Scholar
• NCT01693562 A phase 1/2 study to evaluate MEDI4736. [cited 2018 Dec 17]. Available from: https://clinicaltrials.gov/ct2/show/NCT01693562
   Google Scholar
• Segal NH, Ou SI, Balmanoukian AS, et al. Updated Safety and Efficacy of Durvalumab (MEDI4736) an anti PD-L1 antibody in patients from squamous cell carcinoma of the head and neck. Ann Oncol 2016;27(6):328–350.
   Google Scholar
• Zandberg D. 1042O – durvalumab for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): preliminary results from a single-arm, phase 2 study. Ann Oncol. 2017;28 (supp 5):v372-74.
   Google Scholar
• Topalian SL, Taube JM, Anders RA, et al. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer. 2016;16:275–287.
   PubMed Web of Science ®Google Scholar
• Reck M, Rodriguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375:1823–1833.
   PubMed Web of Science ®Google Scholar
• Wu P, Wu D, Li L, et al. PD-L1 and survival in solid tumors: a meta-analysis. PloS one. 2015;10:e0131403.
   PubMed Web of Science ®Google Scholar
• Wang Q, Liu F, Liu L. Prognostic significance of PD-L1 in solid tumor: an updated meta-analysis. Medicine (Baltimore). 2017;96:e6369.
   PubMed Web of Science ®Google Scholar
• Vassilakopoulou M, Avgeris M, Velcheti V, et al. Evaluation of PD-L1 expression and associated tumor-infiltrating lymphocytes in laryngeal squamous cell carcinoma. Clin Cancer Res off J Am Assoc Cancer Res. 2016;22:704–713.
   PubMed Web of Science ®Google Scholar
• Cohen EE. Phase 1/2b study (SCORES) assesing safety, tolerability and preliminary anti-tumor activity of durvalumab plus AZD 9150 or AZD 5069 in patients wiht solid malignancies and advanced squamous cell carcinoma of the head and neck. Ann Oncol. 2018;29(suppl_8):viii372–viii399.
   Google Scholar
• KEYNOTE-048: phase 3 study of first-line pembrolizumab (P) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). 2018.
   Google Scholar
• Lin YM, Sung WW, Hsieh MJ, et al. High PD-L1 expression correlates with metastasis and poor prognosis in oral squamous cell carcinoma. PloS one. 2015;10:e0142656.
   PubMed Web of Science ®Google Scholar
• Satgunaseelan L, Gupta R, Madore J, et al. Programmed cell death-ligand 1 expression in oral squamous cell carcinoma is associated with an inflammatory phenotype. Pathology. 2016;48:574–580.
   PubMed Web of Science ®Google Scholar
• Rimm DL, Han G, Taube JM, et al. A prospective, multi-institutional, pathologist-based assessment of 4 immunohistochemistry assays for PD-L1 expression in non-small cell lung cancer. JAMA Oncol. 2017;3:1051–1058.
   PubMed Web of Science ®Google Scholar
• Shukuya T, Carbone DP. Predictive markers for the efficacy of anti-PD-1/PD-L1 antibodies in lung cancer. J Thorac Oncol. 2016;11:976–988.
   PubMed Web of Science ®Google Scholar
• McLaughlin J, Han G, Schalper KA, et al. Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer. JAMA Oncol. 2016;2:46–54.
   PubMed Web of Science ®Google Scholar
• Addeo R, Caraglia M, Iuliano G. Pembrolizumab: the value of PDL1 biomarker in head and neck cancer. Expert Opin Biol Ther. 2016;16:1075–1078.
   PubMed Web of Science ®Google Scholar
• Formenti SC, Demaria S. Combining radiotherapy and cancer immunotherapy: a paradigm shift. J Natl Cancer Inst. 2013;105:256–265.
   PubMed Web of Science ®Google Scholar
• Seyedin SN, Schoenhals JE, Lee DA, et al. Strategies for combining immunotherapy with radiation for anticancer therapy. Immunotherapy. 2015;7:967–980.
   PubMed Web of Science ®Google Scholar
• Simone CB 2nd, Burri SH, Heinzerling JH. Novel radiotherapy approaches for lung cancer: combining radiation therapy with targeted and immunotherapies. Transl Lung Cancer Res. 2015;4:545–552.
   PubMed Web of Science ®Google Scholar
• Schoenfeld JD, Mahadevan A, Floyd SR, et al. Ipilmumab and cranial radiation in metastatic melanoma patients: a case series and review. J Immunother Cancer. 2015;3:50.
   PubMed Web of Science ®Google Scholar
• Sridharan V, Margalit DN, Lynch SA, et al. Definitive chemoradiation alters the immunologic landscape and immune checkpoints in head and neck cancer. Br J Cancer. 2016;115:252–260.
   PubMed Web of Science ®Google Scholar
• Lee NY, Ferris RL, Beck JT, et al. JAVELIN head and neck 100: A phase 3 trial of avelumab in combination with chemoradiotherapy (CRT) vs CRT for 1st-line treatment of locally advanced squamous cell carcinoma of the head and neck (LA SCCHN). J clin oncol. 2017;35:TPS6093–TPS6093.
   Google Scholar
• Gillison ML, Ferris RL, Zhang Q, et al. A randomized phase II study of chemoradiation (CRT) ± nivolumab (Nivo) with sequential safety evaluations of Nivo ± lirilumab (Liri) or ipilumumab (Ipi) concomitant with (C) RT in intermediate (IR) and high-risk (HR) head and neck squamous cell carcinoma (HNSCC) (RTOG 3504, NCT02764593). J clin oncol. 2017;35:TPS6097–TPS6097.
   Web of Science ®Google Scholar
• Economopoulou P, Agelaki S, Perisanidis C, et al. The promise of immunotherapy in head and neck squamous cell carcinoma. Ann Oncol. 2016;27:1675–1685.
   PubMedGoogle Scholar
• Hodi FS, Chesney J, Pavlick AC, et al. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol. 2016;17:1558–1568.
   PubMed Web of Science ®Google Scholar
• Wang C, Dickie J, Sutavani RV, et al. Targeting Head and Neck Cancer by Vaccination. Front Immunol. 2018;9:830.
   Web of Science ®Google Scholar
• Aggarwal C, Cohen R, Morrow MP, et al. Immunotherapy with VGX-3100 (HPV16 and HPV18 plasmids) + INO-9012 (DNA encoding IL-12) in human papillomavirus (HPV) associated head and neck squamous cell carcinoma (HNSCCa): interim safety and immunogenicity results. J Immunother Cancer. 2015;3:P426.
   Google Scholar
• Kelly CM, Bowler TG, Munhoz RR, et al. A phase II study of talimogene laherparepvec (T-VEC) and pembrolizumab in patients with metastatic sarcoma. J clin oncol. 2018;36:11516.
   Web of Science ®Google Scholar
• Campbell KS, Purdy AK. Structure/function of human killer cell immunoglobulin-like receptors: lessons from polymorphisms, evolution, crystal structures and mutations. Immunology. 2011;132:315–325.
   PubMed Web of Science ®Google Scholar
• Andrews LP, Marciscano AE, Drake CG, et al. LAG3 (CD223) as a cancer immunotherapy target. Immunol Rev. 2017;276:80–96.
   PubMed Web of Science ®Google Scholar
• McMahan RH, Golden-Mason L, Nishimura MI, et al. Tim-3 expression on PD-1+ HCV-specific human CTLs is associated with viral persistence, and its blockade restores hepatocyte-directed in vitro cytotoxicity. J Clin Invest. 2010;120:4546–4557.
   PubMed Web of Science ®Google Scholar
• Sakuishi K, Apetoh L, Sullivan JM, et al. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med. 2010;207:2187–2194.
   PubMed Web of Science ®Google Scholar
• Hamid O, Bauer TM, Spira AI, et al. Epacadostat plus pembrolizumab in patients with SCCHN: preliminary phase I/II results from ECHO-202/KEYNOTE-037. J clin oncol. 2017;35:6010.
   Web of Science ®Google Scholar
• Harrington KJ, Hingorani M, Tanay MA, et al. Phase I/II study of oncolytic HSV GM-CSF in combination with radiotherapy and cisplatin in untreated stage III/IV squamous cell cancer of the head and neck. Clin Cancer Res off J Am Assoc Cancer Res. 2010;16:4005–4015.
   PubMed Web of Science ®Google Scholar
• Kevin J, Harrington AHK, Mach N, et al. Safety and preliminary efficacy of talimogene laherparepvec (T-VEC) in combination (combo) with pembrobrolizumab (Pembro) in patients (pts) with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M HNSCC): A multicenter, phase 1b study (MASTERKEY-232). Journal of Clinical Oncology. 2018;36(15_suppl):6036-6036.
   Google Scholar
• Economopoulou P, Kotsantis I, Psyrri A. The promise of immunotherapy in head and neck squamous cell carcinoma: combinatorial immunotherapy approaches. ESMO Open. 2016;1:e000122.
   PubMed Web of Science ®Google Scholar
• Lee SJ, Yang A. Immunotherapy for human papillomavirus-associated disease and cervical cancer: review of clinical and translational research. Journal of Gyn Oncol. 2016;27:e51.
   Google Scholar
• Schiller JT, Castellsague X, Garland SM. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine. 2012;30(Suppl 5):F123–138.
   PubMed Web of Science ®Google Scholar
• Gillison ML, Chaturvedi AK, Anderson WF, et al. Epidemiology of human papillomavirus-positive head and neck squamous cell carcinoma. J Clin Oncol. 2015;33:3235–3242.
   PubMed Web of Science ®Google Scholar
• Herrero R, Quint W, Hildesheim A, et al. Reduced prevalence of oral human papillomavirus (HPV) 4 years after bivalent HPV vaccination in a randomized clinical trial in Costa Rica. PloS one. 2013;8:e68329.
   PubMed Web of Science ®Google Scholar
• Rampias T, Sasaki C, Weinberger P, et al. E6 and e7 gene silencing and transformed phenotype of human papillomavirus 16-positive oropharyngeal cancer cells. J Natl Cancer Inst. 2009;101:412–423.
   PubMed Web of Science ®Google Scholar
• Allen CT, Clavijo PE, Van Waes C, et al. Anti-tumor immunity in head and neck cancer: understanding the evidence, how tumors escape and immunotherapeutic approaches. Cancers (Basel). 2015;7:2397–2414.
   PubMed Web of Science ®Google Scholar
• Swiecicki PL, Malloy KM, Worden FP. Advanced oropharyngeal squamous cell carcinoma: pathogenesis, treatment, and novel therapeutic approaches. World J Clin Oncol. 2016;7:15–26.
   PubMed Web of Science ®Google Scholar
• Bartlett DL, Liu Z, Sathaiah M, et al. Oncolytic viruses as therapeutic cancer vaccines. Mol Cancer. 2013;12:103.
   PubMed Web of Science ®Google Scholar
• Nemunaitis J, Ganly I, Khuri F, et al. Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial. Cancer Res. 2000;60:6359–6366.
   PubMed Web of Science ®Google Scholar
• Xu RH, Yuan ZY, Guan ZZ, et al. [Phase II clinical study of intratumoral H101, an E1B deleted adenovirus, in combination with chemotherapy in patients with cancer]. Ai Zheng. 2003;22:1307–1310.
   PubMedGoogle Scholar
• Schuler PJ, Harasymczuk M, Visus C, et al. Phase I dendritic cell p53 peptide vaccine for head and neck cancer. Clin Cancer Res off J Am Assoc Cancer Res. 2014;20:2433–2444.
   PubMed Web of Science ®Google Scholar
• Harrington K Masterkey-232. [cited 2018 Dec 17]. Available from: https://www.youtube.com/watch?v=HIIOaWqzBhY
   Google Scholar
• Khagi Y, Goodman AM, Daniels GA, et al. Hypermutated circulating tumor DNA: correlation with response to checkpoint inhibitor-based immunotherapy. Clin Cancer Res off J Am Assoc Cancer Res. 2017;23:5729–5736.
   PubMed Web of Science ®Google Scholar
• Salas-Vega S, Iliopoulos O, Mossialos E. Assessment of overall survival, quality of life, and safety benefits associated with new cancer medicines. JAMA Oncol. 2017;3:382–390.
   PubMed Web of Science ®Google Scholar